Roger C.Rich Ph.D.


Silicon Valley + 1.650.739.3947

Dr. Roger Rich represents companies in areas of patent law related to biotechnology and pharmaceuticals. He advises clients in the strategic development, management, and prosecution of patent portfolios involving technologies such as small molecule pharmaceuticals, genetic analyses, biologics, nutraceuticals, and transgenic animals, among others. Representative clients have included AbbVie Inc., Acadia Pharmaceuticals, Amgen, AstraZeneca, Becton Dickinson, and Genentech, as well as other start-up companies, established companies, academic institutions, and investment firms.

In addition to patent procurement and portfolio management, Roger advises clients regarding patentability, validity, infringement, and freedom-to-operate issues and performs due diligence evaluations of patent portfolios for possible investment, licensing, or acquisition.


  • Attagene establishes patent portfolio for its product Factorial™Jones Day managed the patent portfolio and prosecuted key patents on behalf of Attagene regarding its Factorial™ platform for profiling multiple signal transduction pathways.
  • BioMarin acquires LEAD TherapeuticsJones Day advised BioMarin Pharmaceutical, Inc. in connection with the acquisition of LEAD Therapeutics, Inc., a small private drug discovery and early stage development company with key compound LT-673, an orally available poly (ADP-ribose) polymerase (PARP) inhibitor for the treatment of patients with rare, genetically defined cancers.
  • BD Diagnostics establishes patent portfolio for molecular diagnostic sepsis testsJones Day represented BD Diagnostics in the establishment of its patent portfolio for molecular diagnostic tests for early prediction of sepsis.
  • Sunesis Pharmaceuticals builds patent portfolio for small molecule oncological drugsJones Day assisted Sunesis Pharmaceuticals, Inc. with the patent prosecution and portfolio management relating to small molecule oncological drugs.
  • Bio-Rad builds patent portfolio for genetic tests for human hemachromatosisJones Day represented Bio-Rad Laboratories, Inc. in connection with its patent portfolio for genetic tests for human hemachromatosis, Bioplex™ 2200 instrumentation for multianalyte detection.
  • WellGen develops patent portfolio for nutrigenomics-derived nutraceutical, dietary supplement and food additive productsJones Day managed patent portfolios for WellGen, Inc. covering its nutrigenomics-derived nutraceutical, dietary supplement, and food additive products and uses.
  • Hana Biosciences maintains patent portfolio for small molecule chemotherapeutic clinical candidate Talvesta™Jones Day managed Hana Biosciences' patent portfolio covering its small molecule chemotherapeutic clinical candidate Talvesta™ (talotrexin).
  • Speaking Engagements

    • March 27, 2019
      Intellectual Property and Plants
    We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.